Completed PHASE3 INTERVENTIONAL 2-arm NCT00249795

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I) (ACTIVE I)

A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation

Sponsor: Bristol-Myers Squibb

Conditions Atrial Fibrillation Cardiovascular Disease

Interventions Irbesartan placebo

Updated 8 times since 2017 Last updated: Sep 29, 2010 Started: Jun 30, 2003 Primary completion: Aug 31, 2009 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Atrial Fibrillation and Cardiovascular Disease and is currently completed. Bristol-Myers Squibb leads this study, which shows 8 recorded versions since 2003 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

8 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE3
Sep 2025 — Oct 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Barcelona, Spain , Berlin, Germany , Bridgewater, United States , Bromma, Sweden , Budapest, Hungary , Buenos Aires, Argentina , Causeway Bay, Hong Kong , Diegem, Belgium , Geneva, Switzerland and 20 more locations